Obesity negatively impacts outcome in elderly female patients with aggressive B ‐cell lymphomas treated with R‐CHOP: results from prospective trials of the German high grade non‐Hodgkin's lymphoma trial group
In conclusion, obesity is a risk factor that influences treatment outcome in elderly female patients with aggressive B‐cell lymphoma treated with R‐CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone). The inferior outcomes in obese female patients may be due to faster rituximab clearance in obese females.
Source: British Journal of Haematology - Category: Hematology Authors: K. Hohloch, B. Altmann, M. Pfreundschuh, M. Loeffler, N. Schmitz, F. Zettl, M. Ziepert, L. Tr ümper Tags: Research Paper Source Type: research
More News: Eating Disorders & Weight Management | Germany Health | Hematology | Lymphoma | Obesity | Prednisolone | Rituxan | Study | UK Health